UAMY Q3 Miss and Guidance Withdrawal Confirm Execution Gap, Downgrade to Sell

What happened

United States Antimony's Q3 fiscal 2026 results missed analyst estimates and the company withdrew its full-year revenue guidance, confirming the execution risks we highlighted after Q2. The prior report had set specific checkpoints for Q3: recognition of the ~$2.6 million deferred DLA shipment and progress toward $9-10 million in government sales, along with margin recovery. The miss and guidance withdrawal indicate these milestones were not met, signaling that DLA order conversion remains stalled and the Thompson Falls ramp has not produced expected throughput. This follows Q2's gross margin collapse to 7% and rising inventory, which we flagged as early warning signs. The stock's negative reaction reflects a rapid repricing away from the smooth ramp narrative, validating our previous 'potential sell' stance and moving us to an outright 'sell' rating.

Implication

The strategic value as a domestic antimony processor remains but is now subordinate to operational execution. Without clear evidence of DLA shipment acceptance, margin recovery above 15%, and inventory conversion over the next two quarters, the equity is likely to face continued multiple compression and potential dilution. The $3.75 attractive entry becomes the new downside anchor if these metrics fail to improve, and only a re-establishment of credible guidance with positive margin trajectory would merit reconsideration.

Thesis delta

Our prior 'POTENTIAL SELL' is upgraded to 'SELL' with conviction raised to 4.5/5. The Q3 miss and guidance withdrawal directly break the condition that Q3 would recognize deferred DLA revenue and show progress toward $9-10M government sales. The base scenario now shifts toward the bear case with an implied value of $4.00, and the trim above level moves down to $5.50 from $6.50.